Biohaven CEO awarded 550,000 stock options

Coric Vlad reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Coric Vlad reported acquisition or exercise transactions in this Form 4 filing.

Biohaven Ltd. Chief Executive Officer Vlad Coric reported receiving a grant of stock options on February 27, 2026. The award covers 550,000 stock options with a stated price per share of $0.00, increasing his directly held option position to 550,000 derivative securities.

According to the footnote, the options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, and each vesting is conditioned on his continuous service with Biohaven on the relevant vesting date.

Insider Trade Summary

Grant/Award: 550,000 shares

Grant/Award 1 txn

Insider Coric Vlad

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	550,000	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to buy) — 550,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Biohaven (BHVN) CEO Vlad Coric report?

Vlad Coric reported an option grant, not a share sale or open-market purchase. He received 550,000 stock options as a derivative security award, increasing his directly held option holdings to 550,000, according to the Form 4 disclosure.

How many stock options were granted to Biohaven CEO Vlad Coric?

The Form 4 shows a grant of 550,000 stock options to Vlad Coric. These are derivative securities with a reported price per share of $0.00, and this grant brings his total directly held options to 550,000 after the transaction.

What is the vesting schedule for Vlad Coric’s Biohaven stock options?

The options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029. Each installment only vests if Vlad Coric remains in continuous service with Biohaven through the applicable vesting date, as described in the Form 4 footnote.

Is Vlad Coric’s Biohaven Form 4 transaction a buy or a grant?

The transaction is classified as a grant or award acquisition, not an open-market buy. The Form 4 uses transaction code “A” and describes it as a grant, reflecting an option award from the company rather than a purchase on an exchange.

What type of security did Vlad Coric acquire in the latest Biohaven filing?

Vlad Coric acquired derivative securities described as “Stock Options (Right to buy).” The grant covers 550,000 options with a reported price per share of $0.00, and is subject to a four-year vesting schedule tied to his continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coric Vlad

(Last) (First) (Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$11.52	02/27/2026		A		550,000		(1)	02/27/2036	Common Shares	550,000	$0	550,000	D

Explanation of Responses:

1. The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Remarks:

	/s/ George Clark, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.